Franchi, Francesco
Rollini, Fabiana
Kairouz, Victor
Rivas Rios, Jose
Rivas, Andrea
Agarwal, Malhar
Briceno, Maryuri
Wali, Mustafa
Nawaz, Ahmed
Silva, Gabriel
Shaikh, Zubair
Maaliki, Naji
Been, Latonya
Piraino, Jason
Pineda, Andres M.
Suryadevara, Siva
Soffer, Daniel
Zenni, Martin M.
Jennings, Lisa K.
Bass, Theodore A.
Angiolillo, Dominick J.
Funding for this research was provided by:
Janssen Pharmaceuticals
Merck
Boehringer Ingelheim
Portola Pharmaceuticals
Gilead Sciences
Amgen
Medicines Company
St. Jude Medical
Bristol-Myers Squibb
Bayer Fund
College of Medicine, University of Florida (NCT02545933, NCT02548650)
Daiichi-Sankyo
CSL Behring
AstraZeneca
Eisai
Eli Lilly and Company
This article is maintained by: Elsevier
Article Title: Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus
Journal Title: JACC: Basic to Translational Science
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.jacbts.2019.07.011
Content Type: article
Copyright: © 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.